An intravenously administered oncolytic virus platform delivers combinations of therapeutic genes specifically to solid tumors to enable a potent anticancer immune response while minimizing systemic toxicity.
Treating solid tumors through the systemic delivery of oncolytic viruses. PsiOxus is very proud to also announce that we have been recognised by Fierce Biotech in this year’s Fierce 15.… read more →
The Sunday Times Hiscox Tech Track 100 league table ranks Britain’s 100 private tech (TMT) companies with the fastest-growing sales over their latest three years.
The philosophy of Fierce 15 is a simple one: We want to see the best science combined with the best and brightest management teams, and we want to see the… read more →
OXFORD, UK and BALTIMORE, MD, USA Avidea Technologies Inc. (“Avidea”), a biotechnology company, and PsiOxus Therapeutics Ltd. (“PsiOxus”), the immuno-oncology company, today announced an agreement licensing PsiOxus’ PolyMAP multivalent adjuvant… read more →
Karen LaRochelle, Chief Business Officer, PsiOxus Therapeutics, was presented with the AstraZeneca Business Development Executive of the Year for her involvement in securing 2 transformational deals with BMS. Karen praised… read more →
OXFORD, United Kingdom (BUSINESS WIRE) PsiOxus Therapeutics, Ltd. (PsiOxus) today announced the appointment of Dr Charles “Charlie” Morris as Chief Development Officer and Karen LaRochelle as Chief Business Officer, both… read more →
NEW YORK and OXFORD, UK – June 30, 2016 Bristol-Myers Squibb Company (NYSE: BMY) and PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an exclusive clinical collaboration agreement to evaluate the safety,… read more →
OXFORD – 10 MARCH 2016 PsiOxus Therapeutics Ltd. (PsiOxus), the immunooncology company, today announced the first treatment of a patient to combine paclitaxel with the oncolytic virotherapy enadenotucirev in the… read more →